# Crona Corp. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Crona Corp.). ## Overview Crona Corp. is a U.S.-based service company focused on disinfection and anti-microbial protection under its ZeroBlast process. It sells infection-control treatments that are applied to facilities and vehicles to reduce germs, viruses, and pathogens for up to 90 days per treatment cycle. ## Products & services • ZeroBlast disinfection and anti-microbial surface protection • Contamination testing for target facilities • Non-toxic coating application for germ control • Re-treatment service every 90 days • Client education and marketing materials for safety promotion - **Disinfection and antimicrobial services** (80%) — Hands-on cleaning, disinfection, and anti-microbial protection services for facilities and vehicles. - **Testing and assessment** (10%) — Pre-treatment contamination testing used to demonstrate infection risk and support service sales. - **Recurring retreatment contracts** (10%) — Scheduled 90-day follow-up treatments that maintain protection and create repeat service revenue. - ZeroBlast disinfection and anti-microbial surface protection - Contamination testing for target facilities - Non-toxic coating application for germ control - Re-treatment service every 90 days - Client education and marketing materials for safety promotion ## Customers Crona sells infection-control services to organizations that need visible hygiene and pathogen-reduction measures in occupied spaces. Its customer base spans commercial, institutional, healthcare, transportation, and residential end markets, with repeat service needs driven by safety, compliance, and public-facing risk management. - **Healthcare and care facilities** (primary) — Hospitals, medical clinics, and care homes buy disinfection services to reduce pathogen spread in high-risk environments. - **Hospitality and food service** (primary) — Restaurants and hotels use the service to improve sanitation visibility and customer confidence. - **Education and public facilities** (secondary) — Classrooms and similar shared spaces buy treatments to lower infection risk in dense occupancy settings. - **Transportation and fleet** (secondary) — Emergency vehicles and fleet vehicles are treated to reduce contamination in high-touch enclosed spaces. - **Commercial and industrial sites** (secondary) — Offices and industrial sites purchase protection for workplace hygiene and operational continuity. - **Residential and sports** (emerging) — Homes and professional sports teams use the service for anti-microbial protection and safety assurance. - Restaurants and hotels seeking visible sanitation and guest confidence - Hospitals, clinics, and care homes needing infection-control support - Schools and classrooms focused on safer shared environments - Fleet operators and emergency vehicles needing rapid decontamination - Industrial sites and offices wanting workplace hygiene protection - Residential homes and sports teams seeking anti-microbial treatment ## Geography Crona is headquartered in the United States, but the filings provided do not disclose meaningful revenue by country or region. The company’s current office is in Vancouver, British Columbia, which suggests a cross-border operating footprint, but the business remains early-stage and revenue has not yet been generated. - Head office is in Vancouver, British Columbia - Country-level revenue disclosure was not provided - Business is described as global in customer application, but not quantified - U.S. filing and U.S. customer examples indicate North American focus - No revenue has been generated yet, so geographic exposure is limited ## Strategy Management’s immediate priority is to secure financing and continue building the service business while operating as an emerging growth company. The filings emphasize a hands-on, recurring-treatment model, but the company’s near-term focus is survival and commercialization rather than expansion, given no revenue, no cash, and a going-concern warning. - **Secure external financing** (short-term) — The company has no cash and needs funding to sustain operations and execute its plan. - **Commercialize recurring infection-control services** (medium-term) — A repeat-treatment model is needed to create durable revenue and customer retention. - **Expand operating capacity** (medium-term) — The company currently has no employees and relies on a sole officer, limiting scale. - Raise additional equity or debt to fund operations - Convert the ZeroBlast process into repeatable service contracts - Use testing and education to support customer adoption - Build management and staffing capacity as funding allows - Maintain compliance across jurisdictions where services are delivered ## Risks Crona faces substantial going-concern and liquidity risk because it has no cash, no revenue, and recurring operating losses. Its service model also depends on customer adoption of a discretionary infection-control offering, while compliance, execution, and staffing constraints could limit growth and raise operating risk. - **Going-concern uncertainty** [critical] — The company has no cash, negative working capital, and expects continued losses and negative cash flow. - **Financing and dilution risk** [high] — Operations depend on additional equity or debt financing, which may be unavailable or expensive. - **Commercialization risk** [high] — The service has not yet generated revenue, so customer adoption and repeat demand are unproven. - **Operational concentration risk** [medium] — The company has no employees and relies on a sole officer/director for execution. - **Regulatory and compliance risk** [medium] — Disinfection services must comply with government rules in each facility and jurisdiction served. - Going-concern risk due to no cash and ongoing losses - Need for external financing may dilute shareholders - No revenue yet, so commercialization remains unproven - Single-officer structure limits execution and scaling capacity - Regulatory compliance burden across service jurisdictions ## Accounting The most important accounting issue is the going-concern assessment, since management and the auditor both highlight substantial doubt about the company’s ability to continue. Investors should also watch debt forgiveness, related-party advances, and share-based compensation, because these items can materially affect reported profit, liabilities, and cash flow despite the absence of operating revenue. - **Going-concern assessment** — May require heightened scrutiny of asset recoverability and financing assumptions - **Debt forgiveness** — Can materially inflate net income without improving core business performance - **Related-party financing** — Important for understanding sustainability of cash resources - **Share-based compensation** — Affects operating expense and net loss comparability - Going-concern disclosure affects asset and liability valuation assumptions - Debt forgiveness can create one-time gains that distort earnings - Related-party advances affect financing cash flow and liquidity analysis - Share-based compensation adds non-cash expense to a pre-revenue business - Depreciation and amortization are material relative to tiny operating scale --- *Last updated: 2026-04-28T19:59:44.339136+00:00*